Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 587 Results
Missed Our Webinar on ACOs? Catch the Archive!
Did you miss this week’s webinar on accountable care organizations (ACOs)? Want to watch the webinar again or share it with your colleagues?
Achieving Quality in ACOs: A Webinar & Infographic
As Accountable Care Organizations (ACOs) gain traction among both private and public payers, so do expectations that these networks of health care providers will improve the quality of patient care…
PCORI Hires AHRQ Director to Head Communication and Dissemination Efforts
The Patient-Centered Outcomes Research Institute (PCORI) is continuing to add to its staff, and its latest hire is a familiar name to those who work in the health outcomes research arena. Jean…
Register today for Leveraging Big Data II: What Does It Mean for Improving Product Development and Health Care?
Since the 1990s, efforts have been made to improve database development and data warehousing by pharmaceutical companies and government entities. A recent emphasis has been placed on "big data," the…
Key Questions That Remain Unanswered & Their Implications for CER
When it comes to comparative effectiveness research (CER), NPC Chief Science Officer Dr. Robert Dubois notes that we’ve seen a lot of progress during the last two years. The Patient-Centered Outcomes…
Relationship Between Individual Patient Differences and Health Outcomes
Despite the widely accepted fact that a patient’s biologic (e.g., age, race, genetic factors) and nonbiologic factors (e.g., social behaviors, dietary habits, geography) affect his or her health…
AMCP 2013 Nexus: Addressing Critical Pharmacy Issues
Specialty pharmacy, health care reform, clinical breakthroughs and research in managed care are among the featured topics at the AMCP 2013 Nexus, a conference taking place at San Antonio’s Henry B…
Four Online Seminars Focus on Impact of Individual Treatment Effects on Drug Therapy
Health care decision-makers interested in understanding how heterogeneity, or individual treatment effects, impact patient health outcomes will benefit from four new online seminars launched today by…
Catch These Upcoming Events and Publications
September was a particularly busy month, featuring a variety of health care conferences, meetings, publications, and ongoing debates about the federal budget and implementation of the health care…
The CER Conversation Continues at the Fifth Comparative Effectiveness Summit
During the summer months, comparative effectiveness research (CER) sparked a number of conversations among health care stakeholders. There were discussions about a New England Journal of Medicine…
One Year Later: The FDA Safety and Innovation Act
We're pleased to share with you a guest post from Cynthia Bens, vice president, public policy, Alliance for Aging Research. It’s been a little over a year since President Obama signed the Food and…
Getting to Know NPC’s Chief Science Officer
This month’s Journal of Comparative Effectiveness Research includes a special interview with NPC’s chief science officer, Dr. Robert Dubois. In the interview with JCER, Dr. Dubois talks about how he…
Rapid Learning Health Systems: Speed Is Good, With Caution
NPC’s Chief Science Officer, Dr. Robert Dubois, and Merck & Co.’s Executive Director, Dr. Newell McElwee, recently authored a column in the Journal of Comparative Effectiveness Research. The…
NPC Seeking Research Proposals on Individual Treatment Effects
The Patient-Centered Outcomes Research Institute isn’t the only organization seeking research proposals—the National Pharmaceutical Council (NPC) is, too!
September 10 NPC Webinar: Can We Bring Clarity, Consistency and Transparency to Payer Coverage Decisions?
What goes into the coverage, or formulary, decisions that health insurers make? A lack of transparency in the process can make it hard to tell. As a result, coverage decisions (and, ultimately,…
Catch NPC Researchers Out and About: The When and Where
The researchers here at NPC have a busy, information-packed month ahead of them. They'll be speaking at various conferences about the use of real-world evidence, pharmaceuticals and bundled payments,…
NPC Webinar: Can We Bring Clarity, Consistency and Transparency to Payer Coverage Decisions?
Why are some treatments covered under a health care plan, while other treatments are not? How do payers evaluate the information needed to make coverage decisions?There is a bit of a "black box"…
Putting Patients First®: Paving a Path to Useful CER
How do patients, providers, and payers know whether health information is credible, accurate, useful or appropriate?Comparative effectiveness research (CER) has the potential to improve health…
NPC Comments on Appointment of AHRQ Director
National Pharmaceutical Council (NPC) President Dan Leonard today released the following statement about the appointment of Richard Kronick, PhD, as the new director of the Agency for Healthcare…
A Step Toward Clear, Consistent, Transparent Formulary Decisions
The process that health insurers use to determine health coverage is not always clear, making it hard for patients, providers and biopharmaceutical manufacturers to predict whether a particular…